Reported Q: Q4 2025 Rev YoY: +14.3% EPS YoY: +30.4% Move: -0.11%
Veeva Systems Inc
VEEV
$183.65 -0.11%
Exchange NYSE Sector Healthcare Industry Medical Healthcare Information Services
Q4 2025
Published: Mar 24, 2025

Company Status Snapshot

Fast view of the latest quarter outcome for VEEV

Reported

Report Date

Mar 24, 2025

Quarter Q4 2025

Revenue

720.89M

YoY: +14.3%

EPS

1.18

YoY: +30.4%

Market Move

-0.11%

Previous quarter: Q3 2025

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

  • Revenue of $720.89M up 14.3% year-over-year
  • EPS of $1.18 increased by 30.4% from previous year
  • Gross margin of 74.9%
  • Net income of 195.63M
  • "“The fourth quarter was a strong finish to a great year for Veeva, with strength across the business and results above guidance. We set our 2030 revenue goal of $6 billion, which reflects the significant opportunity we have ahead.”" - Peter Gassner
VEEV
Company VEEV

Executive Summary

Veeva Systems delivered a solid fourth quarter and a strong fiscal year finish, underscoring durable demand for its Vault platform across life sciences workflows. Q4 2025 revenue of $720.9 million captured broad-based strength in R&D and commercial segments, with gross margin of approximately 74.9% and non-GAAP operating margin of 26.1%. Net income of $195.6 million and earnings per share of $1.20 (GAAP/nongaap) reflect disciplined cost management alongside continued investment in product innovation. For the full year, revenue reached $2.75 billion with non-GAAP operating income of roughly $1.15 billion. Management reiterated a strategy pivot toward AI-enabled workflows and data products, highlighted by the accelerated data-cloud agenda (Compass, OpenData, Pulse) and an expanding Vault CRM footprint among the top 20 customers. The company also reaffirmed its longer-term ambition, including a 2030 revenue target of $6 billion, and signaled that the vast majority of top-20 Vault CRM commitments are expected to occur by 2026. Liquidity remains robust, with substantial net cash generation and a healthy balance sheet, supporting continued investments in product development and go-to-market execution. Investors should monitor (i) the pace of top-20 CRM commitments and data-cloud expansion, (ii) AI-enabled product adoption (CRM Bot, MLR Bot, eTMF/CTMS enhancements), and (iii) potential macro-driven delays in enterprise IT projects, though management contends life sciences remains comparatively resilient to near-term cycles.

Key Performance Indicators

Revenue
Increasing
720.89M
QoQ: 3.10% | YoY: 14.31%
Gross Profit
Increasing
539.90M
74.89% margin
QoQ: 2.87% | YoY: 19.17%
Operating Income
Increasing
188.42M
QoQ: 3.90% | YoY: 39.30%
Net Income
Increasing
195.63M
QoQ: 5.28% | YoY: 32.72%
EPS
Increasing
1.20
QoQ: 4.35% | YoY: 30.43%

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q2 2026 789.08 1.19 +16.7% View
Q1 2026 759.04 1.37 +16.7% View
Q4 2025 720.89 1.18 +14.3% View
Q3 2025 699.21 1.13 +13.4% View
Q2 2025 676.18 1.04 +14.6% View